Drugs in Development: Drug Pipeline

Drug pipeline

The research pipeline identifies drugs currently being tested for psoriasis and/or psoriatic arthritis. The information in this pipeline chart comes from public sources and is as comprehensive as we understand it at the time of update.

The pipeline includes drugs that are in progress through phase II and phase III of clinical trials. The pipeline lists the name of the drug, the drug company, how it is administered, its mechanism of action (or how it works), the phase of study, and the indication (psoriasis or psoriatic arthritis).

Sometimes drugs have two names—the name that is used in the trial and then the brand name for when it is approved. Often the name in the trial is a combination of letters and numbers to indicate the compound's name during development at the drug company.

For terms listed under mechanism of action, view the glossary of terms »

Want updates on the latest psoriatic drugs and research?

Sign up for our Cure e-newsletter and stay current with psoriatic disease research, advancements and treatments.



Therapeutic Approach Status Recent Changes Phase
  • Active Discontinued

Injectables »

Injectables are either subcutaneous (given just under the skin) or intravenous (given into the vein). Both are most commonly used to treat moderate to severe psoriasis.

Injectables »

 
Pre-clinical Phase 1 Phase 2 Phase 3 To Patients
CNTO1959 »
X

CNTO1959Phase: 2


Mechanism: anti-inflammatory (IL-23 blocker)
Indication: Psoriasis
Sponsored by: Janssen
BT-061 »
X

BT-061Phase: 2


Mechanism: immune suppressant
Indication: Psoriasis
Sponsored by: Biotest
Cimzia »
X

CimziaPhase: To patients


Mechanism: anti-inflammatory (TNF blocker)
Indication: Psoriatic Arthritis
Sponsored by: UCB Inc.
Ustekinumab »
X

UstekinumabPhase: To patients


Mechanism: anti-inflammatory (IL-12/23 blocker)
Indication: Psoriasis and Psoriatic Arthritis
Sponsored by: Janssen
Brodalumab (AMG 827) »
X

Brodalumab (AMG 827)Phase: 3


Mechanism: anti-inflammatory (IL-17 receptor blocker)
Indication: Psoriasis
Sponsored by: Amgen
Ixekizumab (LY2439821) »
X

Ixekizumab (LY2439821)Phase: 3


Mechanism: anti-inflammatory (IL-17 blocker)
Indication: Psoriasis
Sponsored by: Eli Lilly & Co.
Secukinumab (AIN457) »
X

Secukinumab (AIN457)Phase: 3


Mechanism: anti-inflammatory (IL-17A blocker)
Indication: Psoriasis and Psoriatic Arthritis
Sponsored by: Novartis
MK-3222/SCH 900222 »
X

MK-3222/SCH 900222Phase: 3


Mechanism: anti-inflammatory (IL-23 blocker)
Indication: Psoriasis
Sponsored by: Merck

Oral Treatments »

Oral treatments are taken by mouth and are usually prescribed for moderate to severe psoriasis and psoriatic arthritis. Oral treatments are a type of systemic medication that works throughout the body.

Oral Treatments »

 
Pre-clinical Phase 1 Phase 2 Phase 3 To Patients
ACT-128800 »
X

ACT-128800Phase: 2


Mechanism: immune suppressant (S1P1 receptor agonist)
Indication: Psoriasis
Sponsored by: Actelion
AEB071 »
X

AEB071Phase: 2


Mechanism: anti-inflammatory (protein kinase C blocker)
Indication: Psoriasis
Sponsored by: Novartis
Alitretinoin »
X

AlitretinoinPhase: 2


Mechanism: skin cell inhibitor (retinoid)
Indication: Psoriasis (pustular)
Sponsored by: Basilea Pharmaceutica
ASP015K »
X

ASP015KPhase: 2


Mechanism: anti-inflammatory (JAK kinase inhibitor)
Indication: Psoriasis
Sponsored by: Astellas Pharma Inc.
Apo805K1 »
X

Apo805K1Phase: 2


Mechanism: proprietary
Indication: Psoriasis
Sponsored by: ApoPharma
BMS-582949 »
X

BMS-582949Phase: 2


Mechanism: anti-inflammatory (p38 MAP kinase blocker)
Indication: Psoriasis
Sponsored by: Bristol-Myers Squibb
FP187 »
X

FP187Phase: 2


Mechanism: anti-inflammatory (fumaric acid)
Indication: Psoriasis
Sponsored by: Forward-Pharma GmbH
Hectoral (Doxercalciferol) »
X

Hectoral (Doxercalciferol)Phase: 2


Mechanism: skin cell inhibitor (vitamin D derivative)
Indication: Psoriasis
Sponsored by: Genzyme
LEO 22811 »
X

LEO 22811Phase: 2


Mechanism: anti-inflammatory (proprietary)
Indication: Psoriasis
Sponsored by: Leo Pharma
Ly3009104 (INCB28050) »
X

Ly3009104 (INCB28050)Phase: 2


Mechanism: anti-inflammatory JAK1 and JAK2 inhibitor
Indication: Psoriasis
Sponsored by: Eli Lilly & Co.
SRT2104 »
X

SRT2104Phase: 2


Mechanism: anti-inflammatory (sirtuin activator)
Indication: Psoriasis
Sponsored by: GlaxoSmithKline
VB-201 »
X

VB-201Phase: 2


Mechanism: anti-inflammatory (oxidized phospholipid)
Indication: Psoriasis
Sponsored by: VBL Therapeutics
IDP-118 »
X

IDP-118Phase: 2


Mechanism: proprietary
Indication: Psoriasis
Sponsored by: Valeant Pharmaceuticals
Apremilast (CC-10004) »
X

Apremilast (CC-10004)Phase: 2


Mechanism: anti-inflammatory (phosphodiesterase-4 inhibitor)
Indication: Psoriasis
Sponsored by: Celgene Corporation
Apremilast (CC-10004) »
X

Apremilast (CC-10004)Phase: 3


Mechanism: anti-inflammatory (phosphodiesterase-4 inhibitor)
Indication: Psoriatic Arthritis
Sponsored by: Celgene Corporation
CF101 »
X

CF101Phase: 3


Mechanism: (adenosine A3 receptor inhibitor)
Indication: Psoriasis
Sponsored by: Can-Fite BioPharma
Tofacitinib (CP-690,550) »
X

Tofacitinib (CP-690,550)Phase: 3


Mechanism: anti-inflammatory (JAK kinase inihibitor)
Indication: Psoriasis and Psoriatic Arthritis
Sponsored by: Pfizer Inc.
Voclosporin (ISA247) »
X

Voclosporin (ISA247)Phase: 3


Mechanism: immune suppressant (calcineurin blocker)
Indication: Psoriasis
Sponsored by: Isotechnika

Topical Treatments »

Topicals are applied to the skin, available either as a prescription or over the counter. They are most commonly used to treat mild psoriasis.

Topical Treatments »

 
Pre-clinical Phase 1 Phase 2 Phase 3 To Patients
AN2728 »
X

AN2728Phase: 1


Mechanism: anti-inflammatory (phosphodiesterase-4 inhibitor)
Indication: Psoriasis
Sponsored by: Anacor Pharmaceuticals Inc.
CT 327 »
X

CT 327Phase: 1


Mechanism: skin cell inhibitor (TrkA kinase blocker)
Indication: Psoriasis
Sponsored by: Creabilis Therapeutics
E6201 »
X

E6201Phase: 1


Mechanism: anti-inflammatory (MEK kinase inhibitor)
Indication: Psoriasis
Sponsored by: Eisai Ltd.
INCB18424 (ruxolintinib) »
X

INCB18424 (ruxolintinib)Phase: 1


Mechanism: anti-inflammatory (JAK kinase inhibitor)
Indication: Psoriasis
Sponsored by: Incyte
LAS41004 »
X

LAS41004Phase: 1


Mechanism: anti-inflammatory/skin cell inhibitor (proprietary)
Indication: Psoriasis
Sponsored by: Almirall, S.A.
LEO 80185 (Taclonex) »
X

LEO 80185 (Taclonex)Phase: 1


Mechanism: anti-inflammatory/skin cell inhibitor (vitamin D/steroid)
Indication: Psoriasis (adolescents)
Sponsored by: LEO Pharma
LEO 90100 »
X

LEO 90100Phase: 1


Mechanism: proprietary
Indication: Psoriasis
Sponsored by: LEO Pharma
PH-10 »
X

PH-10Phase: 1


Mechanism: skin cell inhibitor (Rose Bengal)
Indication: Psoriasis
Sponsored by: Provectus Pharmaceuticals
WBI-1001 »
X

WBI-1001Phase: 1


Mechanism: anti-inflammatory (proprietary)
Indication: Psoriasis
Sponsored by: Welichem Biotech Inc.
Ruxolitinib »
X

RuxolitinibPhase: 1


Mechanism: anti-inflammatory (JAK kinase inhibitor)
Indication: Psoriasis
Sponsored by: Incyte Corporation - Novartis
Calcipotriene foam (STF 115469) »
X

Calcipotriene foam (STF 115469)Phase: 2


Mechanism: skin cell inhibitor vitamin D3 analog
Indication: Psoriasis (pediatric, ages 2-11)
Sponsored by: GlaxoSmithKline
Tofacitinib (CP-690,550) »
X

Tofacitinib (CP-690,550)Phase: 2


Mechanism: anti-inflammatory (JAK kinase inhibitor)
Indication: Psoriasis
Sponsored by: Pfizer Inc.
M518101 »
X

M518101Phase: 2


Mechanism: anti-inflammatory/skin cell inhibitor (proprietary)
Indication: Psoriasis
Sponsored by: Maruho Co. Ltd.
CycloPsorb™ »
X

CycloPsorb™Phase: Pre-clinical


Mechanism: Immunosuppressant (calcineurin inhibitor) with proprietary SPACE peptide
Indication: Psoriasis
Sponsored by: Convoy Therapeutics